Stevanato Group S.p.A. (NYSE:STVN) Shares Acquired by Zions Bancorporation N.A.

Zions Bancorporation N.A. increased its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 29.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 68,017 shares of the company’s stock after acquiring an additional 15,555 shares during the quarter. Zions Bancorporation N.A.’s holdings in Stevanato Group were worth $1,482,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of STVN. Van Berkom & Associates Inc. acquired a new position in Stevanato Group in the 4th quarter valued at about $39,000. PNC Financial Services Group Inc. lifted its holdings in Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock valued at $123,000 after acquiring an additional 5,291 shares during the last quarter. US Bancorp DE grew its position in Stevanato Group by 17.9% in the fourth quarter. US Bancorp DE now owns 8,527 shares of the company’s stock worth $186,000 after acquiring an additional 1,295 shares during the period. Marco Investment Management LLC acquired a new stake in Stevanato Group during the fourth quarter worth $203,000. Finally, Hardy Reed LLC raised its position in Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after purchasing an additional 840 shares during the period.

Stevanato Group Price Performance

Stevanato Group stock opened at €21.26 ($22.86) on Wednesday. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. Stevanato Group S.p.A. has a 52-week low of €16.56 ($17.81) and a 52-week high of €33.49 ($36.01). The firm has a market cap of $6.44 billion, a PE ratio of 45.23, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60. The company’s 50 day moving average is €21.03 and its two-hundred day moving average is €20.59.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The business had revenue of €352.68 million for the quarter, compared to analysts’ expectations of €346.26 million. On average, research analysts expect that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on STVN shares. UBS Group cut their price objective on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research report on Friday, March 7th. Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Bank of America upped their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Wolfe Research assumed coverage on shares of Stevanato Group in a report on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price for the company. Finally, William Blair reissued an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy” and a consensus target price of €25.70 ($27.63).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.